Arimixyl

KALPA PHARMACEUTICALS ARIMIXYL

Arimixyl is an oral medication containing anastrozole as its active substance, with each tablet providing 1 mg of this aromatase inhibitor.

DRUG COMPOSITION

Each Arimixyl tablet comprises 1 mg of anastrozole, a potent aromatase inhibitor used to regulate estrogen levels.

PHARMACEUTICAL FORM

Arimixyl is formulated as an oral tablet, ensuring convenient and precise dosing.

PHARMACEUTICAL GROUP AND ATC CODE

Pharmaceutical group: Antineoplastic and immunomodulating agents; ATC code: L02BG03.

PHARMACOLOGICAL PROPERTIES

Anastrozole selectively inhibits aromatase, the enzyme responsible for converting androgens into estrogens. By reducing estrogen levels, Arimixyl is effective in treating estrogen-dependent conditions.

PROFILE

• Chemical name: 2,2'-[5-(1H-1,2,4-triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropanenitrile)
• Chemical formula: C17H19N5
• Percentage of anabolic activity: Not a steroid
• Percentage of androgenic activity: Not a steroid
• Active half life: Approximately 46 hours
• Recommended dosage: 1 mg per day for breast cancer; may vary in other applications
• Acne: Not reported
• Bloating (water retention): Not reported
• HBR: Low
• Hepatic toxicity: Rare
• Aromatization: Inhibits aromatase, reducing estrogen conversion

THERAPEUTICAL INDICATIONS

Arimixyl is indicated for the treatment of hormone receptor-positive breast cancer in postmenopausal women. It is also employed off-label in hormone replacement therapy (HRT) for transgender individuals.

DOSES AND METHOD OF ADMINISTRATION

The typical dose of Arimixyl for breast cancer is 1 mg once daily. Dosage adjustments may be made based on individual patient response.

CYCLE/STACKING

Solo cycle:

• Arimixyl is primarily used as a supportive therapy and is not typically administered in solo cycles.

Cutting cycle:

• Incorporated into cutting cycles to manage estrogen-related side effects of aromatizable steroids.

Bulking cycle:

• Used in bulking cycles to control estrogen levels when aromatizable compounds are part of the stack.

POST CYCLE THERAPY

PCT may include Arimixyl to prevent estrogen-related side effects. For example:

• Arimixyl: 0.5 mg every other day for 4 weeks

SIDE EFFECTS

Potential side effects include joint pain, hot flashes, and an impact on bone mineral density. Regular medical monitoring is advised.

CONTRAINDICATIONS

Contraindications include hypersensitivity to anastrozole, premenopausal women, and individuals with a history of estrogen-sensitive cancers.

OVERDOSE

No specific overdose symptoms are reported. In case of overdose, supportive measures should be taken, and medical attention sought.

WARNINGS AND SPECIAL PRECAUTIONS FOR USE:

Arimixyl may affect bone health; therefore, monitoring bone mineral density is recommended. Caution is advised in patients with cardiovascular risk factors.

INTERACTIONS WITH OTHER DRUGS

Arimixyl may interact with medications affecting liver enzymes. Consultation with a healthcare professional is essential.

PRESENTATION, PACKAGING

30 tablets.

STORAGE

Arimixyl should be stored according to the manufacturer's instructions, typically in a cool, dry place, and kept out of the reach of children.

LEGAL STATUS

The legal status of Arimixyl may vary by jurisdiction. It is typically available only with a prescription.

LAB TEST RESULTS

DATE OF LAST TEXT CHECKS

/

NAME AND ADDRESS OF THE MANUFACTURER

Kalpa Pharmaceuticals
India

EXTERNAL LINKS

• Anastrozole Wiki, wikipedia.org
• Anastrozole Uses, Side Effects & Warnings, drugs.com
• Anastrozole Oral: Uses, Side Effects, Interactions, Pictures, webmd.com.